Marketing
-
New Alzheimer's drugs
Eisai’s Alzheimer’s drug Leqembi approved in Japan
Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.
By Ned Pagliarulo • Sept. 25, 2023 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
New RSV vaccines can be powerful tools, but rollout poses test
Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID-19 and flu.
By Delilah Alvarado • Sept. 18, 2023 -
Explore the Trendline➔
Brian Tucker / BioPharma DiveTrendlinePharma, new drugs and market strategy
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet
The drug, known scientifically as momelotinib, is now cleared to treat myelofibrosis and will compete against rival medicines sold by Incyte and Bristol Myers Squibb.
By Jacob Bell • Sept. 18, 2023 -
J&J to phase out Janssen name in corporate rebrand
Janssen will be recast as Johnson & Johnson Innovative Medicine, melding the drugs division’s identity more closely with its parent.
By Ned Pagliarulo • Sept. 15, 2023 -
Insulin pump-makers grapple with questions about GLP-1s
New weight loss drugs have sparked a stock selloff for some device makers, but medtech analysts don’t see them a likely to undermine the companies’ business — yet.
By Elise Reuter • Sept. 14, 2023 -
Akili cuts 40% of workforce, plans shift to non-prescription model
The digital therapeutics company expects to extend its cash runway into 2025 with the changes.
By Elise Reuter • Sept. 13, 2023 -
CDC endorses new COVID boosters as focus turns to rollout
This fall will now feature vaccination campaigns for COVID-19, influenza and respiratory syncytial virus.
By Delilah Alvarado • Sept. 13, 2023 -
Sponsored by Alexander Group
Do not miss the return to growth
The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.
By Alexander Group • Sept. 5, 2023 -
FTC allows Amgen’s $28B deal for Horizon to go through, with conditions
The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.
By Jonathan Gardner • Sept. 1, 2023 -
FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon
Urged by a judge, the antitrust regulator said it wants to start discussions “regarding the proper resolution of this matter” — a potential prelude to a settlement.
By Jonathan Gardner • Aug. 28, 2023 -
AstraZeneca the latest pharma to challenge drug pricing law
The drugmaker's lawsuit follows similar legal challenges from Merck & Co., Bristol Myers Squibb and Johnson & Johnson, among others.
By Ned Pagliarulo • Aug. 25, 2023 -
FDA approves Novartis’ copycat of blockbuster Biogen drug
According to one analyst, the approval was the last hurdle keeping Sandoz’s Tyruko from directly competing in the U.S. market against Biogen’s inflammation-regulating medicine Tysabri.
By Jacob Bell • Updated Aug. 25, 2023 -
Boehringer sues to block US drug price program
The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.
By Ned Pagliarulo • Aug. 22, 2023 -
Amazon Pharmacy expands insulin manufacturer coupons
The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.
By Rebecca Pifer • Aug. 17, 2023 -
Dexcom, Abbott ramp up DTC marketing in fight for growing diabetes market
As insurers cover continuous glucose monitors for more people, device makers are taking a page from the pharma marketing playbook.
By Elise Reuter • Aug. 17, 2023 -
Amylyx ALS drug sales tick higher after fast US launch
In Europe, however, the biotech is appealing a negative decision from regulators that has for now blocked its path to market there.
By Ned Pagliarulo • Aug. 11, 2023 -
Novartis sickle cell drug’s approval formally revoked by EU regulators
The company said it would withdraw the drug, Adakveo, from the EU market after the European Commission endorsed an earlier EMA recommendation.
By Ned Pagliarulo • Aug. 4, 2023 -
Q&A
With OTC birth control approved, access battles have just begun
Perrigo received the first FDA approval for an over-the-counter birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.
By Karissa Waddick • July 31, 2023 -
Apellis faces safety doubts for fast-selling eye drug
At a medical meeting, the company confirmed seven cases of a rare, but severe, side effect have been reported following treatment with its geographic atrophy drug Syfovre.
By Ben Fidler • Updated July 31, 2023 -
Apellis shares sink on reports of rare side effects with new vision loss drug
An organization of retinal specialists flagged six cases of severe eye inflammation from commercial use of Syfovre. Apellis says the drug’s safety profile is consistent with testing.
By Ben Fidler • July 17, 2023 -
More convenient form of Roche MS drug succeeds in study
The under-the-skin formulation of Ocrevus can be administered in 10 minutes, versus a longer period for the current intravenous version.
By Kristin Jensen • July 13, 2023 -
Obesity drugs
EMA expands probe of possible suicide risk to popular weight loss, diabetes drugs
The European drug regulator says it now has 150 reports of possible cases involving self-injury and suicidal thoughts among people taking GLP-1 medicines like Ozempic.
By Kristin Jensen • July 12, 2023 -
Illumina hit by EU with maximum fine for Grail acquisition
The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.
By Susan Kelly • July 12, 2023 -
Bausch + Lomb bulks up OTC business with J&J deal
The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.
By Ned Pagliarulo • July 6, 2023 -
With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy
The agency granted a long-awaited clearance last Thursday, but unexpected aspects of the hemophilia treatment’s label had some investors worried about its commercial prospects.
By Jacob Bell • June 30, 2023